Lyell Immunopharma presented updated safety and translational data for its CAR T-cell therapy, ronde-cel, in treating relapsed or refractory large B-cell lymphoma (LBCL). Over 100 patients treated showed no severe cytokine release syndrome (CRS) and low neurotoxicity, supporting outpatient use. The therapy's dual-targeting of CD19/CD20 and enrichment of memory T cells may explain durable responses. Key clinical trial updates are expected in late 2026 and mid-2027, with plans for regulatory submission thereafter.
Cornerstone has released an updated version of the EPA's GHG Emission Factors Hub, providing free, consolidated data for scopes 1, 2, and 3 greenhouse gas emissions. This update includes new factors for air travel, refrigerants, and aligns with the l...
Ascendis Pharma reported positive five-year results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) for adult hypoparathyroidism. The therapy maintained stable calcium levels, kidney and bone health, and quality of life, all...
SpaceX began trading on the stock market at $150 per share, above its IPO price of $135, marking the largest public offering in history and valuing the company at about $1.96 trillion. The shares quickly rose to $165, reflecting strong demand that ex...
Space ETFs fell significantly on the day SpaceX launched its IPO, priced at $135 per share with a $1.77 trillion valuation, raising $75 billion in the largest IPO ever. The sell-off reflects investors rotating out of other space stocks to buy SpaceX ...
Park Ha Biological Technology announced a strategic partnership with Star Plus Action to integrate AI technology into skincare and healthcare services. This collaboration aims to create an intelligent service ecosystem in the beauty and wellness indu...
